Safety
ADVERSE EVENT
All patients in all cohorts experienced at least one AE (Safety summary.AE, adverse event; Atezo, atezolizumab; Dara, daratumumab; Dex, dexamethasone; Len, lenalidomide; Pom, pomalidomide; SAE, serious adverse event.*Cohort A: Atezo monotherapy; B1: Atezo+Len; C: Atezo+Len; D1/D2/D3: Atezo+Dara; E1: Atezo+Dara+Len; F1/F2: Atezo+Dara+Pom; F3: Dara+Pom+Dex."-" means not applicable.Median duration of exposure to Atezo was between 1.4 months (range: 0.0–12.4) in Cohort D3 to 41.5 months (range: 8.8–53.8) in Cohort D1 (